PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinomaXian-De Liu, Eric Jonasch|Nature Communications|2020Cited by 173
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional LandscapeZixing Wang, Kanishka Sircar, Tae Beom Kim et al.|Clinical Cancer Research|2017Cited by 94
Preventive medicine of von Hippel–Lindau disease-associated pancreatic neuroendocrine tumorsTobias Krauß, Roland Därr, Alfonso Massimiliano Ferrara et al.|Endocrine Related Cancer|2018Cited by 67
Noninvasive detection of any-stage cancer using free glycosaminoglycansSiniša Bratulić, Francesco Gatto, Angelo Limeta et al.|Proceedings of the National Academy of Sciences|2022Cited by 63
Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew Leonard Laccetti, Matthew T. Campbell, Rajan T. Gupta et al.|Cancer Medicine|2021Cited by 19